A series of novel diarylpyrimidine analogues featuring a hydroxyiminomethyl group between the pyrimidine scaffold and the aryl wing I have been synthesized and tested in MT-4 cells culture as non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus (HIV). Most of these new congeners exhibited moderate to excellent activity against wild-type virus with an EC 50 value ranging from 0.569μM to 0.005μM. 4-(4-((Hydroxyimino) (3-methoxyphenyl)methyl)pyrimidin-2-ylamino)benzonitrile (12n) was identified as the most active compound of this new series (EC 50 =0.025μM, SI >1223) associated with moderate activity against HIV-1 double mutant strains (K103N+Y181C) (EC 50 =8.72μM) in addition to its anti-HIV-2 activity with an EC 50 value of 8.31μM. Preliminary structure–activity relationship (SAR) among the newly synthesized DAPYs was also investigated.